Ono Pharmaceutical Co., Ltd. (4528.T)
| Previous close | 2,324.00 |
| Open | 2,344.50 |
| Bid | 2,298.00 x 0 |
| Ask | 2,305.50 x 0 |
| Day's range | 2,293.50 - 2,344.50 |
| 52-week range | 2,232.50 - 2,966.50 |
| Volume | |
| Avg. volume | 2,180,866 |
| Market cap | 1.083T |
| Beta (5Y monthly) | 0.20 |
| PE ratio (TTM) | 8.73 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 80.00 (3.47%) |
| Ex-dividend date | 28 Mar 2024 |
| 1y target est | N/A |
- Reuters
Japan's Ono Pharma says $2.4 billion Deciphera purchase 'first step' for global expansion
Japan's Ono Pharmaceutical Co said on Tuesday its $2.4 billion takeover of Deciphera Pharmaceuticals is a "first step" in expanding in U.S. and European markets. With this deal, Ono Pharma joins Japanese rivals Takeda Pharmaceutical and Astellas Pharma which have spent big recently to replenish their drug pipelines. Ono Pharma is best known globally for its blockbuster cancer drug Opdivo, which is sold in the U.S. by partner Bristol-Myers Squibb.
- Reuters
Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion
Japan's Ono Pharmaceutical Co said on Tuesday its $2.4 billion takeover of Deciphera Pharmaceuticals is a "first step" in expanding in U.S. and European markets. With this deal, Ono Pharma joins Japanese rivals Takeda Pharmaceutical and Astellas Pharma which have spent big recently to replenish their drug pipelines. Ono Pharma is best known globally for its blockbuster cancer drug Opdivo, which is sold in the U.S. by partner Bristol-Myers Squibb.
- Investor's Business Daily
Deciphera Catapults 73% On Ono Pharmaceutical's $2.4 Billion Takeover
Deciphera stock rocketed to a three-year high Monday after Ono Pharmaceutical agreed to buy it for $2.4 billion.
